IPCI - IntelliPharmaCeutics International Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.454569
-0.006231 (-1.35%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close0.460800
Open0.470000
Bid0.440500 x 900
Ask0.460000 x 800
Day's Range0.450000 - 0.480000
52 Week Range0.320000 - 2.920000
Volume146,803
Avg. Volume243,460
Market Cap19.505M
Beta0.67
PE Ratio (TTM)N/A
EPS (TTM)-0.311000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.75
Trade prices are not sourced from all markets
  • ACCESSWIRE15 days ago

    Intellipharmaceutics Receives Anticipated Additional Staff Determination Letter from NASDAQ

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received a letter from Nasdaq Listings Qualification staff (the "Staff") formally notifying the Company that its 180-day grace period for the $1.00 per share bid price requirement period has expiredand that therefore the Company is non-compliant with Nasdaq Listing Rule 5550(a)(2). While the Company understands has the opportunity to provide a submission to the Nasdaq Hearings Panel (the''Panel''), it does not intend to do so since the Company proactively addressed the bid price issue at the hearing held on May 17, 2018, and since Panel has already granted the Company a further extension within which to address the bid price issue.

  • ACCESSWIRElast month

    Nasdaq Hearings Panel Grants Intellipharmaceutics' Request for Continued Listing

    TORONTO, ON / ACCESSWIRE / May 22, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received notice from the Nasdaq Hearings Panel granting its request for continued listing until September 28, 2018 while the Company works to regain compliance with Nasdaq's requirements. At a hearing held on May 17, 2018, the Company presented its plan to regain and maintain compliance with Nasdaq's continued listing requirements.

  • ACCESSWIRElast month

    Intellipharmaceutics Reports Director Election Results

    TORONTO, ON / ACCESSWIRE / May 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI; TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, ...

  • ACCESSWIRE2 months ago

    Intellipharmaceutics Announces Start of Intranasal Human Abuse Liability Studies for Oxycodone ER

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has commenced its Category 2 and 3 human abuse liability studies for the Company's Oxycodone ER product candidate to support its abuse-deterrent label claims for the intranasal route of administration. "This is a very important step towards resubmission of our NDA for Oxycodone ER," commented Dr. Isa Odidi, CEO of Intellipharmaceutics.

  • ACCESSWIRE2 months ago

    Intellipharmaceutics Files Appeal to Nasdaq Delisting Determination

    TORONTO, ON / ACCESSWIRE / April 27, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI; TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the ...

  • ACCESSWIRE2 months ago

    Wired News – Asterias Biotherapeutics: Clinical Grade Lot Released to Support Dosing of Subjects in First Clinical Study of AST-VAC2 in Non-Small Cell Lung Cancer

    LONDON, UK / ACCESSWIRE / April 27, 2018 / Active-Investors.com has just released a free research report on Asterias Biotherapeutics, Inc. (NYSE: AST) ("Asterias"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AST as the Company's latest news hit the wire. On April 25, 2018, the California-based biotechnology Company announced that Cancer Research UK has released the first cGMP (current Good Manufacturing Practice) clinical grade lot of AST-VAC2 to be used to dose subjects enrolling into the first clinical study evaluating AST-VAC2 in non-small cell lung cancer (NSCLC).

  • ACCESSWIRE2 months ago

    Intellipharmaceutics Receives Delisting Determination from NASDAQ Staff; Company to Request Hearing

    TORONTO, ON / ACCESSWIRE / April 23, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Staff has determined to delist the Company's securities from Nasdaq. On September 20, 2017, Staff notified the Company that it did not comply with the minimum $2.5 million stockholders' equity, $35 million market value of listed securities, or $500,000 of net income from continuing operations requirements set forth in Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), or 5550(b)(3), respectively.

  • ACCESSWIRE2 months ago

    Intellipharmaceutics Announces First Quarter 2018 Results

    TORONTO, ON / ACCESSWIRE / April 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company ...

  • ACCESSWIRE3 months ago

    Intellipharmaceutics Announces Closing of US$1.8 Million Financing

    TORONTO, ON / ACCESSWIRE / March 21, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing ...

  • ACCESSWIRE3 months ago

    Intellipharmaceutics Announces US$1.8 Million Registered Direct Offering

    TORONTO, ON / ACCESSWIRE / March 19, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing ...

  • ACCESSWIRE3 months ago

    Intellipharmaceutics Announces Closing of US$3.5 Million Financing

    TORONTO, ON / ACCESSWIRE / March 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing ...

  • ACCESSWIRE3 months ago

    Intellipharmaceutics Announces US$3.5 Million Registered Direct Offering

    TORONTO, ON / ACCESSWIRE / March 14, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing ...

  • ACCESSWIRE4 months ago

    Intellipharmaceutics Announces Fiscal Year 2017 Results

    TORONTO, ON / ACCESSWIRE / February 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI, TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company ...

  • ACCESSWIRE4 months ago

    Intellipharmaceutics Sets Earnings Release Date for Year End 2017 Results

    TORONTO, ON / ACCESSWIRE / February 13, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in ...

  • ACCESSWIRE4 months ago

    Intellipharmaceutics Meets with FDA Regarding Oxycodone ER NDA Development Program

    TORONTO, ON / ACCESSWIRE / February 9, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company ...

  • ACCESSWIRE7 months ago

    Corporate News Blog - Valeant Pharma Sells Sprout Pharma’s Subsidiary Back to Original Shareholders

    Research Desk Line-up: IntelliPharmaCeutics Intl. Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 8, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines ...

  • Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: Q3, 2017 By the Numbers : October 13, 2017
    Capital Cube8 months ago

    Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: Q3, 2017 By the Numbers : October 13, 2017

    Categories: Yahoo FinanceGet free summary analysis Intellipharmaceutics International, Inc. reports financial results for the quarter ended August 31, 2017. Highlights Summary numbers: Revenues of USD 1.19 million, Net Earnings of USD -2.55 million. Change in operating cash flow of 62.25% compared to same period last year is about the same as change in earnings, likely no significant ... Read more (Read more...)

  • New Strong Sell Stocks for October 11th
    Zacks8 months ago

    New Strong Sell Stocks for October 11th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • Associated Press8 months ago

    Intellipharmaceutics reports 3Q loss

    The Toronto-based company said it had a loss of 8 cents per share. The extended-release drug developer posted revenue of $1.2 million in the period. In the final minutes of trading on Tuesday, the company's ...